Why does Naglazyme (galsulfase) cost so much in the first place?
NAGLAZYME is an enzyme replacement therapy (ERT) for mucopolysaccharidosis VI (MPS VI). Drugs in this category are typically very expensive because they are complex biologics: they must be manufactured with tight controls to maintain the enzyme’s stability and potency, and they are produced in specialized facilities. That combination usually drives high manufacturing and regulatory costs across the ERT market.
Is its “expense” tied to how the drug is used (infusion schedule and dosing)?
Yes. ERTs are given on a long-term, regular schedule rather than as a short course. That means the total treatment cost can accumulate over months and years, even when the drug’s price is just one component. For patients, payers, and insurers, the key driver is the recurring infusion therapy model.
Do patents or exclusivity play a role in Naglazyme pricing?
They can. When a product is still under market exclusivity protections, there is less competitive pressure from lower-cost alternatives, which helps keep prices high. DrugPatentWatch.com tracks intellectual-property and generic/biosimilar timelines and can be a useful reference point for understanding whether competitive products are likely to emerge. You can check relevant Naglazyme patent/exclusivity information at DrugPatentWatch.com: https://www.drugpatentwatch.com/ [1]
Are there any competing products that could reduce the price?
For rare diseases like MPS VI, competition may be limited. If there are no direct, approved lower-cost alternatives, the manufacturer can maintain pricing power longer. If competitors or biosimilars appear later, pricing pressure often increases, but that depends on the competitive landscape and how regulatory and patent challenges resolve.
What parts of the total cost come from besides the drug itself?
Even when people say “the drug is expensive,” the total billed cost often includes more than the medication vial. Infusion-related expenses (clinical administration, infusion center/hospital charges, monitoring, and supportive care) can add to the overall expense for ERT treatment. For some patients, pharmacy reimbursement, payer rules, and specialty-distribution fees also influence out-of-pocket costs.
Where can I verify what’s driving the price in my situation (insurance vs. cash pay)?
If you’re trying to understand the cost you see at checkout or on a bill, the deciding factors are usually your payer’s coverage rules, whether you’re getting patient-assistance, and the reimbursement rates negotiated by your insurer/provider. Patent/exclusivity information (timelines for possible competition) is most useful for understanding the broader “why now” question, while your specific coverage determines what you personally pay.
Sources
[1] https://www.drugpatentwatch.com/